![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at Upcoming Investor Conferences
September 24, 2013 13:32 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today
announced presentations at upcoming investor conferences.
Hans GCP Schikan, Chief Executive...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy
September 20, 2013 07:00 ET
|
Prosensa Holding N.V.
LONDON and LEIDEN, Netherlands, Sept. 20, 2013 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Prosensa today announced that GSK's Phase III clinical study of drisapersen, an investigational antisense...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053
September 06, 2013 08:30 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 6, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments
August 28, 2013 07:00 ET
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Aug. 28, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding N.V. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on August 28, 2013
August 20, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 20, 2013 (GLOBE NEWSWIRE) --
Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Wednesday, August...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at Wedbush 2013 Life Sciences Management Access Conference
August 06, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
GCP Schikan, Chief Executive Officer, will present a corporate
overview at the...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Awarded EUR 6 million EU FP7 Research Grant
August 01, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding B.V. Prices Initial Public Offering
June 27, 2013 18:56 ET
|
Prosensa Holding N.V.
LEIDEN, the Netherlands, June 27, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding B.V. ("Prosensa") announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an...